Moderna Inc at Goldman Sachs Global Healthcare Conference Transcript
Good afternoon. Thanks, everyone, for joining us. I'm Salveen Richter, one of the biotech technology analysts at Goldman Sachs. And we're pleased to have the team from Moderna here today. We have Stéphane Bancel, CEO; and Lorence Kim, CFO.
Questions & Answers
So maybe to start, just given your recent IPO, could you just provide us with a brief overview of the company, the mRNA technology and your modality approach to drug development?
© -
Okay. Good. So thank you so much for having us today. So Moderna, as many of you know, are using messenger RNA to make medicine inside people's body. We believe this is a new class of medicine that provides a very large product opportunity, because to further the protein coding in the human genome are not [drug-able] using recombinant technology. Because it's a
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |